$BMRN Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in BIOMARIN PHARMACEUTICAL INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in BIOMARIN PHARMACEUTICAL INC. Get notifications about new insider transactions in BIOMARIN PHARMACEUTICAL INC for free.
Page: < prev 1 2 3 4 5 6 7 ... 34 next >
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 26 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 21.51 | 10,000 | 215,100 | 337,080 | 327.1 K to 337.1 K (+3.06 %) |
| Nov 26 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | L | 75.38 | 10 | 754 | 327,080 | 327.1 K to 327.1 K (0.00 %) |
| Nov 26 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Gift | G | 0.00 | 450 | 0 | 327,070 | 327.5 K to 327.1 K (-0.14 %) |
| Oct 29 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 21.51 | 5,000 | 107,550 | 133,000 | |
| Oct 29 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 69.55 | 5,000 | 347,750 | 327,520 | 332.5 K to 327.5 K (-1.50 %) |
| Oct 29 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 21.51 | 5,000 | 107,550 | 332,520 | 327.5 K to 332.5 K (+1.53 %) |
| Sep 30 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 21.51 | 1,000 | 21,510 | 138,000 | |
| Sep 30 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 21.51 | 1,000 | 21,510 | 138,000 | |
| Sep 30 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 21.51 | 1,000 | 21,510 | 327,520 | 326.5 K to 327.5 K (+0.31 %) |
| Sep 30 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 21.51 | 1,000 | 21,510 | 327,520 | 326.5 K to 327.5 K (+0.31 %) |
| Sep 18 2019 | BMRN | BIOMARIN PHARMACEU ... | LAWLIS V BRYAN | Director | Option Exercise | M | 21.51 | 3,750 | 80,663 | 7,500 | |
| Sep 18 2019 | BMRN | BIOMARIN PHARMACEU ... | LAWLIS V BRYAN | Director | Sell | S | 74.47 | 3,750 | 279,263 | 23,590 | 27.3 K to 23.6 K (-13.72 %) |
| Sep 18 2019 | BMRN | BIOMARIN PHARMACEU ... | LAWLIS V BRYAN | Director | Buy | M | 21.51 | 3,750 | 80,663 | 27,340 | 23.6 K to 27.3 K (+15.90 %) |
| Aug 08 2019 | BMRN | BIOMARIN PHARMACEU ... | HERON ELAINE J | Director | Option Exercise | M | 63.10 | 1,553 | 97,994 | 5,047 | |
| Aug 08 2019 | BMRN | BIOMARIN PHARMACEU ... | HERON ELAINE J | Director | Buy | M | 63.10 | 1,553 | 97,994 | 47,668 | 46.1 K to 47.7 K (+3.37 %) |
| Jul 12 2019 | BMRN | BIOMARIN PHARMACEU ... | MEIER RICHARD A | Director | Gift | G | 0.00 | 6,000 | 0 | 80,040 | 86 K to 80 K (-6.97 %) |
| Jul 11 2019 | BMRN | BIOMARIN PHARMACEU ... | ANDERSON ELIZABETH M | Director | Grant | A | 0.00 | 4,490 | 0 | 4,490 | 0 to 4.5 K |
| Jun 19 2019 | BMRN | BIOMARIN PHARMACEU ... | LAWLIS V BRYAN | Director | Option Exercise | M | 21.51 | 3,750 | 80,663 | 11,250 | |
| Jun 19 2019 | BMRN | BIOMARIN PHARMACEU ... | LAWLIS V BRYAN | Director | Sell | S | 81.08 | 3,750 | 304,050 | 23,590 | 27.3 K to 23.6 K (-13.72 %) |
| Jun 19 2019 | BMRN | BIOMARIN PHARMACEU ... | LAWLIS V BRYAN | Director | Buy | M | 21.51 | 3,750 | 80,663 | 27,340 | 23.6 K to 27.3 K (+15.90 %) |
| Jun 10 2019 | BMRN | BIOMARIN PHARMACEU ... | BAFFI ROBERT | President, Global M ... | Grant | A | 68.78 | 309 | 21,254 | 107,727 | 107.4 K to 107.7 K (+0.29 %) |
| Jun 07 2019 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Gift | G | 0.00 | 300 | 0 | 71,899 | 72.2 K to 71.9 K (-0.42 %) |
| Jun 07 2019 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Grant | A | 68.78 | 309 | 21,254 | 72,199 | 71.9 K to 72.2 K (+0.43 %) |
| Jun 07 2019 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Grant | A | 68.78 | 309 | 21,254 | 61,994 | 61.7 K to 62 K (+0.50 %) |
| Jun 07 2019 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Grant | A | 68.78 | 309 | 21,254 | 124,845 | 124.5 K to 124.8 K (+0.25 %) |
| Jun 07 2019 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Grant | A | 68.78 | 176 | 12,106 | 47,686 | 47.5 K to 47.7 K (+0.37 %) |
| Jun 07 2019 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Finance and CA ... | Grant | A | 68.78 | 299 | 20,566 | 13,959 | 13.7 K to 14 K (+2.19 %) |
| Jun 06 2019 | BMRN | BIOMARIN PHARMACEU ... | MEIER RICHARD A | Director | Grant | A | 0.00 | 4,430 | 0 | 86,040 | 81.6 K to 86 K (+5.43 %) |
| Jun 06 2019 | BMRN | BIOMARIN PHARMACEU ... | HOMBACH ROBERT J. | Director | Grant | A | 0.00 | 4,430 | 0 | 11,910 | 7.5 K to 11.9 K (+59.22 %) |
| Jun 06 2019 | BMRN | BIOMARIN PHARMACEU ... | Dere Willard H | Director | Grant | A | 0.00 | 4,430 | 0 | 13,420 | 9 K to 13.4 K (+49.28 %) |
| Jun 06 2019 | BMRN | BIOMARIN PHARMACEU ... | HERON ELAINE J | Director | Grant | A | 0.00 | 4,430 | 0 | 46,115 | 41.7 K to 46.1 K (+10.63 %) |
| Jun 06 2019 | BMRN | BIOMARIN PHARMACEU ... | LAWLIS V BRYAN | Director | Grant | A | 0.00 | 4,430 | 0 | 23,590 | 19.2 K to 23.6 K (+23.12 %) |
| Jun 06 2019 | BMRN | BIOMARIN PHARMACEU ... | Slamon Dennis | Director | Grant | A | 0.00 | 4,430 | 0 | 18,615 | 14.2 K to 18.6 K (+31.23 %) |
| Jun 06 2019 | BMRN | BIOMARIN PHARMACEU ... | LEWIS ALAN | Director | Grant | A | 0.00 | 4,430 | 0 | 25,590 | 21.2 K to 25.6 K (+20.94 %) |
| Jun 06 2019 | BMRN | BIOMARIN PHARMACEU ... | GREY MICHAEL G | Director | Grant | A | 0.00 | 4,430 | 0 | 38,540 | 34.1 K to 38.5 K (+12.99 %) |
| Jun 06 2019 | BMRN | BIOMARIN PHARMACEU ... | PYOTT DAVID E I | Director | Grant | A | 0.00 | 4,430 | 0 | 13,640 | 9.2 K to 13.6 K (+48.10 %) |
| Jun 06 2019 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Grant | A | 0.00 | 14,160 | 0 | 61,635 | 47.5 K to 61.6 K (+29.83 %) |
| Jun 06 2019 | BMRN | BIOMARIN PHARMACEU ... | BAFFI ROBERT | President, Global M ... | Grant | A | 0.00 | 14,160 | 0 | 107,418 | 93.3 K to 107.4 K (+15.18 %) |
| May 14 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 14.39 | 10,000 | 143,900 | 0 | |
| May 14 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 82.52 | 10,000 | 825,193 | 326,520 | 336.5 K to 326.5 K (-2.97 %) |
| May 14 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 14.39 | 10,000 | 143,900 | 336,520 | 326.5 K to 336.5 K (+3.06 %) |
| May 13 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 14.39 | 4,000 | 57,560 | 10,000 | |
| May 13 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 81.97 | 4,000 | 327,888 | 326,520 | 330.5 K to 326.5 K (-1.21 %) |
| May 13 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 14.39 | 4,000 | 57,560 | 330,520 | 326.5 K to 330.5 K (+1.23 %) |
| May 09 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 14.39 | 4,000 | 57,560 | 14,000 | |
| May 09 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 82.16 | 4,000 | 328,625 | 326,520 | 330.5 K to 326.5 K (-1.21 %) |
| May 09 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 14.39 | 4,000 | 57,560 | 330,520 | 326.5 K to 330.5 K (+1.23 %) |
| May 09 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Grant | A | 68.78 | 309 | 21,254 | 326,520 | 326.2 K to 326.5 K (+0.09 %) |
| Apr 30 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 14.39 | 3,000 | 43,170 | 18,000 | |
| Apr 30 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 84.41 | 200 | 16,881 | 326,211 | 326.4 K to 326.2 K (-0.06 %) |
| Apr 30 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 83.59 | 800 | 66,870 | 326,411 | 327.2 K to 326.4 K (-0.24 %) |
| Apr 30 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 82.44 | 2,000 | 164,889 | 327,211 | 329.2 K to 327.2 K (-0.61 %) |
| Apr 30 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 14.39 | 3,000 | 43,170 | 329,211 | 326.2 K to 329.2 K (+0.92 %) |
| Apr 18 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 21.51 | 1,000 | 21,510 | 139,000 | |
| Apr 18 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 21.51 | 1,000 | 21,510 | 326,211 | 325.2 K to 326.2 K (+0.31 %) |
| Apr 15 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 14.39 | 4,000 | 57,560 | 21,000 | |
| Apr 15 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 14.39 | 1,000 | 14,390 | 25,000 | |
| Apr 15 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 89.12 | 4,000 | 356,480 | 325,211 | 329.2 K to 325.2 K (-1.22 %) |
| Apr 15 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 14.39 | 4,000 | 57,560 | 329,211 | 325.2 K to 329.2 K (+1.23 %) |
| Apr 15 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 14.39 | 1,000 | 14,390 | 325,211 | 324.2 K to 325.2 K (+0.31 %) |
| Apr 09 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 14.39 | 3,000 | 43,170 | 29,000 | |
| Apr 09 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 93.67 | 700 | 65,572 | 324,211 | 324.9 K to 324.2 K (-0.22 %) |
| Apr 09 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 92.39 | 100 | 9,239 | 324,911 | 325 K to 324.9 K (-0.03 %) |
| Apr 09 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 91.27 | 2,200 | 200,787 | 325,011 | 327.2 K to 325 K (-0.67 %) |
| Apr 09 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 14.39 | 3,000 | 43,170 | 327,211 | 324.2 K to 327.2 K (+0.93 %) |
| Apr 09 2019 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Sell | S | 94.00 | 2,953 | 277,582 | 13,660 | 16.6 K to 13.7 K (-17.78 %) |
| Apr 09 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 14.39 | 3,000 | 43,170 | 29,000 | |
| Apr 09 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 93.37 | 3,000 | 280,114 | 324,211 | 327.2 K to 324.2 K (-0.92 %) |
| Apr 09 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 14.39 | 3,000 | 43,170 | 327,211 | 324.2 K to 327.2 K (+0.93 %) |
| Apr 03 2019 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Sell | S | 89.00 | 13,473 | 1,199,097 | 47,510 | 61 K to 47.5 K (-22.09 %) |
| Mar 29 2019 | BMRN | BIOMARIN PHARMACEU ... | LAWLIS V BRYAN | Director | Option Exercise | M | 14.39 | 2,150 | 30,939 | 0 | |
| Mar 29 2019 | BMRN | BIOMARIN PHARMACEU ... | LAWLIS V BRYAN | Director | Sell | S | 89.76 | 2,150 | 192,984 | 19,160 | 21.3 K to 19.2 K (-10.09 %) |
| Mar 29 2019 | BMRN | BIOMARIN PHARMACEU ... | LAWLIS V BRYAN | Director | Buy | M | 14.39 | 2,150 | 30,939 | 21,310 | 19.2 K to 21.3 K (+11.22 %) |
| Mar 29 2019 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Sell | S | 90.00 | 100 | 9,000 | 60,983 | 61.1 K to 61 K (-0.16 %) |
| Mar 29 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 14.39 | 1,000 | 14,390 | 32,000 | |
| Mar 29 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 14.39 | 1,000 | 14,390 | 324,211 | 323.2 K to 324.2 K (+0.31 %) |
| Mar 27 2019 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 89.18 | 3,656 | 326,025 | 47,475 | 51.1 K to 47.5 K (-7.15 %) |
| Mar 26 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 14.39 | 4,000 | 57,560 | 33,000 | |
| Mar 26 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 87.86 | 4,000 | 351,440 | 323,211 | 327.2 K to 323.2 K (-1.22 %) |
| Mar 26 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 14.39 | 4,000 | 57,560 | 327,211 | 323.2 K to 327.2 K (+1.24 %) |
| Mar 26 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Payment of Exercise | F | 88.05 | 13,127 | 1,155,832 | 323,211 | 336.3 K to 323.2 K (-3.90 %) |
| Mar 26 2019 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Payment of Exercise | F | 88.05 | 3,598 | 316,804 | 51,131 | 54.7 K to 51.1 K (-6.57 %) |
| Mar 26 2019 | BMRN | BIOMARIN PHARMACEU ... | BAFFI ROBERT | EVP, Technical Oper ... | Payment of Exercise | F | 88.05 | 3,501 | 308,263 | 93,258 | 96.8 K to 93.3 K (-3.62 %) |
| Mar 26 2019 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Payment of Exercise | F | 88.05 | 415 | 36,541 | 16,613 | 17 K to 16.6 K (-2.44 %) |
| Mar 26 2019 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Payment of Exercise | F | 88.05 | 3,598 | 316,804 | 61,083 | 64.7 K to 61.1 K (-5.56 %) |
| Mar 26 2019 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Sell | S | 87.86 | 5,932 | 521,186 | 124,536 | 130.5 K to 124.5 K (-4.55 %) |
| Mar 26 2019 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Payment of Exercise | F | 88.05 | 5,836 | 513,860 | 130,468 | 136.3 K to 130.5 K (-4.28 %) |
| Mar 26 2019 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Sell | S | 87.86 | 3,363 | 295,473 | 71,890 | 75.3 K to 71.9 K (-4.47 %) |
| Mar 26 2019 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Payment of Exercise | F | 88.05 | 3,309 | 291,357 | 75,253 | 78.6 K to 75.3 K (-4.21 %) |
| Mar 25 2019 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 90.47 | 1,930 | 174,614 | 54,729 | 56.7 K to 54.7 K (-3.41 %) |
| Mar 25 2019 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 89.62 | 2,589 | 232,020 | 56,659 | 59.2 K to 56.7 K (-4.37 %) |
| Mar 21 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 14.39 | 1,000 | 14,390 | 37,000 | |
| Mar 21 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 14.39 | 1,000 | 14,390 | 336,338 | 335.3 K to 336.3 K (+0.30 %) |
| Mar 21 2019 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Sell | S | 93.92 | 7,907 | 742,625 | 78,562 | 86.5 K to 78.6 K (-9.14 %) |
| Mar 21 2019 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 93.07 | 3,728 | 346,965 | 59,248 | 63 K to 59.2 K (-5.92 %) |
| Mar 19 2019 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Option Exercise | A | 94.53 | 23,450 | 2,216,729 | 23,450 | |
| Mar 19 2019 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Grant | A | 0.00 | 9,370 | 0 | 64,681 | 55.3 K to 64.7 K (+16.94 %) |
| Mar 19 2019 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Payment of Exercise | F | 94.53 | 7,227 | 683,168 | 55,311 | 62.5 K to 55.3 K (-11.56 %) |
| Mar 19 2019 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Option Exercise | A | 94.53 | 9,650 | 912,215 | 9,650 | |
| Mar 19 2019 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Grant | A | 0.00 | 5,780 | 0 | 17,028 | 11.2 K to 17 K (+51.39 %) |
| Mar 19 2019 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Payment of Exercise | F | 94.53 | 1,149 | 108,615 | 11,248 | 12.4 K to 11.2 K (-9.27 %) |
| Mar 19 2019 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Option Exercise | A | 94.53 | 32,160 | 3,040,085 | 32,160 | |
| Mar 19 2019 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Sell | S | 94.09 | 9,597 | 902,982 | 136,304 | 145.9 K to 136.3 K (-6.58 %) |
| Mar 19 2019 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Grant | A | 0.00 | 12,840 | 0 | 145,901 | 133.1 K to 145.9 K (+9.65 %) |
| Mar 19 2019 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Payment of Exercise | F | 94.53 | 9,443 | 892,647 | 133,061 | 142.5 K to 133.1 K (-6.63 %) |
| Mar 19 2019 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Option Exercise | A | 94.53 | 23,450 | 2,216,729 | 23,450 | |
| Mar 19 2019 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Grant | A | 0.00 | 9,370 | 0 | 86,469 | 77.1 K to 86.5 K (+12.15 %) |
| Mar 19 2019 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Payment of Exercise | F | 94.53 | 6,648 | 628,435 | 77,099 | 83.7 K to 77.1 K (-7.94 %) |
| Mar 19 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 14.39 | 4,000 | 57,560 | 38,000 | |
| Mar 19 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | A | 94.53 | 87,080 | 8,231,672 | 87,080 | |
| Mar 19 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 94.40 | 4,000 | 377,600 | 335,338 | 339.3 K to 335.3 K (-1.18 %) |
| Mar 19 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 14.39 | 4,000 | 57,560 | 339,338 | 335.3 K to 339.3 K (+1.19 %) |
| Mar 19 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Grant | A | 0.00 | 34,780 | 0 | 335,338 | 300.6 K to 335.3 K (+11.57 %) |
| Mar 19 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Payment of Exercise | F | 94.53 | 28,143 | 2,660,358 | 300,558 | 328.7 K to 300.6 K (-8.56 %) |
| Mar 19 2019 | BMRN | BIOMARIN PHARMACEU ... | BAFFI ROBERT | EVP, Technical Oper ... | Option Exercise | A | 94.53 | 24,120 | 2,280,064 | 24,120 | |
| Mar 19 2019 | BMRN | BIOMARIN PHARMACEU ... | BAFFI ROBERT | EVP, Technical Oper ... | Grant | A | 0.00 | 9,630 | 0 | 96,759 | 87.1 K to 96.8 K (+11.05 %) |
| Mar 19 2019 | BMRN | BIOMARIN PHARMACEU ... | BAFFI ROBERT | EVP, Technical Oper ... | Payment of Exercise | F | 94.53 | 7,083 | 669,556 | 87,129 | 94.2 K to 87.1 K (-7.52 %) |
| Mar 19 2019 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Option Exercise | A | 94.53 | 23,450 | 2,216,729 | 23,450 | |
| Mar 19 2019 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Grant | A | 0.00 | 9,370 | 0 | 62,976 | 53.6 K to 63 K (+17.48 %) |
| Mar 19 2019 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Payment of Exercise | F | 94.53 | 7,169 | 677,686 | 53,606 | 60.8 K to 53.6 K (-11.80 %) |
| Mar 14 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 14.39 | 3,000 | 43,170 | 42,000 | |
| Mar 14 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 93.42 | 3,000 | 280,253 | 328,701 | 331.7 K to 328.7 K (-0.90 %) |
| Mar 14 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 14.39 | 3,000 | 43,170 | 331,701 | 328.7 K to 331.7 K (+0.91 %) |
| Mar 13 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 14.39 | 4,000 | 57,560 | 45,000 | |
| Mar 13 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 14.39 | 5,000 | 71,950 | 49,000 | |
| Mar 13 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 91.44 | 4,000 | 365,770 | 328,701 | 332.7 K to 328.7 K (-1.20 %) |
| Mar 13 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 14.39 | 4,000 | 57,560 | 332,701 | 328.7 K to 332.7 K (+1.22 %) |
| Mar 13 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 88.96 | 5,000 | 444,780 | 328,701 | 333.7 K to 328.7 K (-1.50 %) |
| Mar 13 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 14.39 | 5,000 | 71,950 | 333,701 | 328.7 K to 333.7 K (+1.52 %) |
| Mar 08 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 14.39 | 4,000 | 57,560 | 54,000 | |
| Mar 08 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 14.39 | 4,000 | 57,560 | 54,000 | |
| Mar 08 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 90.78 | 4,000 | 363,120 | 328,701 | 332.7 K to 328.7 K (-1.20 %) |
| Mar 08 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 90.78 | 4,000 | 363,120 | 328,701 | 332.7 K to 328.7 K (-1.20 %) |
| Mar 08 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 14.39 | 4,000 | 57,560 | 332,701 | 328.7 K to 332.7 K (+1.22 %) |
| Mar 08 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 14.39 | 4,000 | 57,560 | 332,701 | 328.7 K to 332.7 K (+1.22 %) |
| Mar 06 2019 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Sell | S | 95.00 | 2,196 | 208,620 | 142,504 | 144.7 K to 142.5 K (-1.52 %) |
| Mar 05 2019 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Payment of Exercise | F | 94.76 | 912 | 86,421 | 62,538 | 63.5 K to 62.5 K (-1.44 %) |
| Mar 05 2019 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Grant | A | 0.00 | 12,205 | 0 | 63,450 | 51.2 K to 63.5 K (+23.82 %) |
| Mar 05 2019 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Payment of Exercise | F | 94.76 | 1,154 | 109,353 | 144,700 | 145.9 K to 144.7 K (-0.79 %) |
| Mar 05 2019 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Grant | A | 0.00 | 15,687 | 0 | 145,854 | 130.2 K to 145.9 K (+12.05 %) |
| Mar 05 2019 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Payment of Exercise | F | 94.76 | 840 | 79,598 | 83,747 | 84.6 K to 83.7 K (-0.99 %) |
| Mar 05 2019 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Grant | A | 0.00 | 11,853 | 0 | 84,587 | 72.7 K to 84.6 K (+16.30 %) |
| Mar 05 2019 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Payment of Exercise | F | 94.76 | 917 | 86,895 | 60,775 | 61.7 K to 60.8 K (-1.49 %) |
| Mar 05 2019 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Grant | A | 0.00 | 12,557 | 0 | 61,692 | 49.1 K to 61.7 K (+25.56 %) |
| Mar 05 2019 | BMRN | BIOMARIN PHARMACEU ... | BAFFI ROBERT | EVP, Technical Oper ... | Payment of Exercise | F | 94.76 | 917 | 86,895 | 94,212 | 95.1 K to 94.2 K (-0.96 %) |
| Mar 05 2019 | BMRN | BIOMARIN PHARMACEU ... | BAFFI ROBERT | EVP, Technical Oper ... | Grant | A | 0.00 | 11,853 | 0 | 95,129 | 83.3 K to 95.1 K (+14.23 %) |
| Mar 05 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Payment of Exercise | F | 94.76 | 4,909 | 465,177 | 328,701 | 333.6 K to 328.7 K (-1.47 %) |
| Mar 05 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Grant | A | 0.00 | 45,320 | 0 | 333,610 | 288.3 K to 333.6 K (+15.72 %) |
| Feb 28 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 14.39 | 4,000 | 57,560 | 58,000 | |
| Feb 28 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 91.78 | 4,000 | 367,120 | 288,290 | 292.3 K to 288.3 K (-1.37 %) |